Skip to main content
Retour
VCYT logo

Veracyte, Inc.

Qualité des données : 100%
VCYT
NASDAQ Healthcare Biotechnology
32,94 €
▼ 0,60 € (-1,79%)
Cap. Boursière : 2,62B
Fourchette du Jour
32,17 € 33,36 €
Fourchette 52 Semaines
22,61 € 50,71 €
Volume
945 398
Moyenne 50J / 200J
37,13 € / 34,68 €
Clôture Précédente
33,54 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 39,5 0,3
P/B 2,0 2,9
ROE % 5,3 3,7
Net Margin % 12,8 3,8
Rev Growth 5Y % 23,9 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
44,50 € +35.1%
Low: 37,00 € High: 50,00 €
P/E Prévisionnel
20,2
BPA Prévisionnel
1,66 €
Croissance BPA (est.)
+0,0%
CA Est.
580 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,13 €
2,09 € – 2,16 €
850 M 1
FY2029 2,03 €
1,99 € – 2,06 €
780 M 1
FY2028 1,90 €
1,58 € – 2,14 €
710 M 3

Points Clés

Revenue grew 23,89% annually over 5 years — strong growth
Earnings grew 174,89% over the past year
Debt/Equity of 0,03 — conservative balance sheet
Generating 126,63M in free cash flow
P/E of 39,45 — premium valuation
PEG of 0,31 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
23,89%
Revenue (1Y)16,01%
Earnings (1Y)174,89%
FCF Growth (3Y)92,25%

Qualité

Return on Equity
5,34%
ROIC4,12%
Net Margin12,83%
Op. Margin14,34%

Sécurité

Debt / Equity
0,03
Current Ratio8,15
Interest Coverage0,00

Valorisation

P/E Ratio
39,45
P/B Ratio2,00
EV/EBITDA30,94
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,01% Revenue Growth (3Y) 19,68%
Earnings Growth (1Y) 174,89% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 23,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 517,15M Net Income (TTM) 66,35M
ROE 5,34% ROA 4,72%
Gross Margin 69,62% Operating Margin 14,34%
Net Margin 12,83% Free Cash Flow (TTM) 126,63M
ROIC 4,12% FCF Growth (3Y) 92,25%
Safety
Debt / Equity 0,03 Current Ratio 8,15
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 39,45 P/B Ratio 2,00
P/S Ratio 5,06 PEG Ratio 0,31
EV/EBITDA 30,94 Dividend Yield 0,00%
Market Cap 2,62B Enterprise Value 2,29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 517,15M 445,76M 361,05M 296,54M 219,51M
Net Income 66,35M 24,14M -74,40M -36,56M -75,56M
EPS (Diluted) 0,82 0,31 -1,02 -0,51 -1,11
Gross Profit 360,05M 298,15M 248,15M 194,95M 145,11M
Operating Income 74,15M 16,14M -85,80M -41,08M -81,90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,41B 1,30B 1,11B 1,16B 1,19B
Total Liabilities 96,44M 124,07M 70,80M 81,22M 91,31M
Shareholders' Equity 1,31B 1,18B 1,04B 1,08B 1,10B
Total Debt 39,65M 50,74M 12,63M 14,72M 18,85M
Cash & Equivalents 362,58M 239,09M 216,45M 154,25M 173,20M
Current Assets 488,38M 372,27M 285,62M 248,64M 243,10M
Current Liabilities 59,94M 78,63M 61,24M 62,61M 64,15M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#846 of 1052
29

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026